Fig. 3From: Biokinetic and dosimetric aspects of 64CuCl2 in human prostate cancer: possible theranostic implicationsBox plot representation of PVE corrected SUVmean and SUVmax values 1Â h after tracer injection, the effective half-life, the time-integrated activity coefficient and the absorbed dose (per administrated activity) for the three sites of diseaseBack to article page